Oral anabolic androgenic steroid

Methandienone (Dianabol)

Methandienone (Dianabol) is an oral anabolic steroid that WADA prohibits at all times and the US lists in Schedule III; the app's half-life figure is ~4.5 hours.1,2

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Methandienone (Dianabol) after one dose: 50% at ~4.5 h, 25% at 9 h, 12.5% at 13.5 h.

Drawn from the half-life in the app's model, ~4.5 h. The model's figures

Methandienone, also written metandienone and methandrostenolone, is an anabolic steroid with the chemical name 17beta-hydroxy-17alpha-methylandrosta-1,4-dien-3-one.3 Dianabol is a brand name for it: a 1975 trial in the British Journal of Sports Medicine is titled as a trial of "methandienone (Dianabol, CIBA)".4 The International Programme on Chemical Safety (IPCS) monograph on methandienone, written by R. E. Ferner in 1994, states that it is harmonised with the group monograph on anabolic steroids (PIM G007).3

The WADA 2026 Prohibited List names metandienone, when administered exogenously, in class S1.1, anabolic androgenic steroids, which is prohibited at all times, in and out of competition.1 In the US, 21 CFR 1308.13 lists methandienone among the anabolic steroids in Schedule III.2 In the UK, Part III of Schedule 2 to the Misuse of Drugs Act 1971, headed Class C drugs, lists methandienone.5

Two double-blind crossover trials of 100 mg a day for 6 weeks in athletic men, by Hervey and colleagues in 1976 and 1981, reported weight gain on methandienone.6,7 Strength and performance did not differ significantly between drug and placebo in the 1976 trial, and increased significantly on the drug but not on placebo in the 1981 trial.6,7

Reported adverse findings include a significant rise in systolic blood pressure and three withdrawals in a 13-person trial, impaired glucose tolerance with a markedly increased insulin response in 9 patients, and single case reports of cholestatic jaundice, hepatitis and, in two children, virilization (with adrenal suppression in the boy), three of them in people also taking other drugs (stanozolol; anti-estrogens and diuretics; cyproheptadine).8,9,10,11,12

Reported in people

The IPCS monograph states that anabolic steroids bind to specific receptors present especially in reproductive tissue, muscle and fat, and that in practice all agents of the class possess both anabolic and androgenic properties to some degree.3 The same monograph states: "There is no clear evidence that anabolic steroids enhance overall athletic performance", citing Elashoff and colleagues, 1991.3 In the 1981 repeat, body potassium rose by 436 mmol (+/- SEM 41) and body nitrogen by 255 g (+/- 69) with a weight gain of 2.3 kg (+/- 0.4).7 The authors wrote that these increases were too large in proportion to the weight gain to be attributed to gain of normal muscle or other lean tissue, and implied "gain of nitrogen-rich, phosphate-poor substance".7

In tissue preparations and metabolism studies

In a 1984 study by Saartok and colleagues, steroids were tested as competitors for binding of [3H]methyltrienolone to the androgen receptor in rat and rabbit skeletal muscle and in rat prostate.13 Binding of methanedienone was weak, with relative binding affinity values less than 0.05.13 In 2012, Parr and colleagues reported that in enzyme tests the human mitochondrial enzymes CYP11B1 and CYP11B2 were capable of metabolizing metandienone, and that analysis of urine after oral administration of metandienone to one volunteer and of its rearrangement product NorMD to another confirmed their contribution.14

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~4.5 h
Bioavailability
95%
Typical dose
10–50 mg/day
Route
Oral
Time to peak
~1.5 h

The app lists a half-life of ~4.5 hours for methandienone. In its general section on anabolic steroids, the IPCS monograph states that "the elimination half-life from plasma is very short" and prints no number.3 That sentence sits in a passage that goes on to say the duration of biological effects is "determined almost entirely by the rate of absorption from subcutaneous or intramuscular depots, and on the de-esterification which precedes it".3

Table 3.1Half-life and pharmacokinetics6 rows
ParameterApp valueSource figure
Half-life~4.5 hoursIn its general section on anabolic steroids, the IPCS monograph states that the elimination half-life from plasma is "very short" and prints no number.3
Bioavailability (oral)~95%The IPCS monograph prints no percentage; it states that oral dosing involves extensive first-pass hepatic metabolism for all anabolic steroids except those substituted at the 17-alpha position.3
Time to peak~1.5 hoursThe IPCS monograph prints no time to peak; it states that absorption after oral dosing is rapid for testosterone and probably for other anabolic steroids.3
RouteOralGiven by mouth at 10 to 50 mg daily in a 1999 case report, and by oral administration in a 1991 excretion study.15,16
Typical dose10 to 50 mg/dayDoses in the trials below ran from 2.5 mg daily to 100 mg/day.17,6
Markers to monitorLiver enzymes, lipids, hematocritThe IPCS monograph lists hepatic function tests, cholesterol concentration and a full blood count among tests relevant in the investigation of chronic anabolic steroid abuse.3

After oral administration of metandienone to male volunteers, Schänzer, Geyer and Donike reported in 1991 that unconjugated metabolites reached maximum excretion rates between 4 and 12 h after administration and conjugated metabolites III, IV and V between 12 and 34 h.16 These are timings of metabolites in urine, not a concentration curve of methandienone in plasma.16 In 2006, Schänzer and colleagues reported a new long-term metabolite in urine up to 19 days after a single dose of 5 mg.18

4

Human studies

Table 4.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Freed and colleagues, 19758Double-blind crossover; no sponsor stated in the PubMed record13 experienced male weightlifters on high-protein diets and regular exercise10 or 25 mg/day; length not statedImprovements significantly greater than on placebo; body weight rose, seemingly with water retention; systolic blood pressure rose significantly; three men withdrew because of side effects, which disappeared after the drug was stopped.
Hervey and colleagues, 19766Double-blind crossover; no sponsor stated in the PubMed record11 athletic men during weight-training100 mg/day for 6 weeksAgainst placebo, weight rose a mean 3.3 kg (+/- 0.6) and body potassium 420 mmol (+/- 68), with the weight gain confined to the lean part of the body (authors: may be intracellular fluid); strength and performance did not differ significantly; plasma cortisol rose and plasma testosterone fell.
Hervey and colleagues, 19817Double-blind crossover, 6-week periods separated by 6 weeks; no sponsor stated in the PubMed record7 male weight-lifters in regular training100 mg/day, 6 weeksBody weight, potassium, nitrogen, muscle size, leg performance and strength increased significantly on the drug but not on placebo; weight gain 2.3 kg (+/- 0.4).
Chesnut and colleagues, 197719Double-blind placebo-controlled; no sponsor stated in the PubMed record26 postmenopausal women with osteoporosis; 16 completed (10 treated, 6 placebo)Dose not stated; 26 monthsTotal body calcium rose 2% on methandrostenolone and fell 3% on placebo in completers (p less than 0.01 for the difference); the authors wrote that the data strongly suggest long-term use prevented bone loss and that a rise above initial values is "less certain".
Aloia and colleagues, 198120Double-blind, randomized, parallel, placebo-controlled; no sponsor stated in the PubMed recordPeople with osteoporosis; number not statedDose not stated; 24 monthsTotal body potassium rose in the treated group, mainly in the first 6 months; bone mass did not change significantly except total body calcium at 6 months, +11 g against -6 g on placebo (p = .05).
Inkovaara and colleagues, 198317Double-blind placebo-controlled, all combinations of three agents; no sponsor stated in the PubMed record327 people over 65 (57 men), mean age 79.5Methandienone 2.5 mg daily, with or without calcium carbonate 3 g and vitamin D3 1000 iu, for 9 monthsFractures more frequent on placebo, not significantly; coronary mortality higher among those on all three agents; with two treatments the increase in coronary deaths was not significant, but pooling the two-treatment groups against those on one or neither showed a significant increase, most (P less than 0.001) for vitamin D3 with methandienone; authors: methandienone reduced osteoporotic activity and increased muscular mass most effectively.
Godsland and colleagues, 19869Patients off and on treatment; no sponsor stated in the PubMed record9 patientsDose and length not statedOn treatment: markedly increased insulin response with impaired glucose tolerance; fasting glucose and insulin significantly reduced; sensitivity of glucose disposal to insulin reduced by a factor of 4.

Deeper analysis: Hervey and colleagues, 1976

Hervey and colleagues (Lancet, 1976) gave methandienone to 11 athletic men during a course of weight-training, in a double-blind, crossover experiment at 100 mg/day for 6 weeks.6 Compared with the placebo period, the men gained weight and accumulated potassium, the weight gain was confined to the lean part of the body, and the muscles increased in size, while strength and performance improved over each training period but not significantly differently on drug and placebo.6 The authors wrote that the weight and body-composition changes "may alternatively have been caused by an increase in intracellular fluid, and the question of anabolic action therefore remains open".6 The PubMed record gives no sponsor, affiliations or adverse events.6

Deeper analysis: Hervey and colleagues, 1981

Hervey and colleagues (Clinical Science, 1981) repeated the trial in seven male weight-lifters in regular training, adding measurements of total body nitrogen, with 100 mg of methandienone a day given alternately with placebo in 6-week periods separated by 6 weeks.7 In the repeat, body weight, potassium and nitrogen, muscle size, and leg performance and strength increased significantly on the drug but not on placebo.7 They wrote that the finding of increased body nitrogen suggested the weight gain was "not only intracellular fluid", and concluded that "Although this action of methandienone might be described as anabolic, the weight gain produced is not normal muscle".7 The PubMed record gives no sponsor, affiliations or adverse events.7

Deeper analysis: Freed and colleagues, 1975

Freed and colleagues (British Medical Journal, 1975) ran a double-blind crossover trial of methandienone 10 or 25 mg/day in 13 experienced male weightlifters taking high-protein diets and regular exercise, to see whether the drug improved athletic performance.8 Improvements were significantly greater on methandienone than on placebo, body weights rose, and systolic blood pressure rose significantly.8 The authors reported that methandienone caused many side effects, that three men had to withdraw because of them, and that all side effects disappeared after the drug was stopped.8 The PubMed record gives no sponsor, affiliations or stated limitations.8

Deeper analysis: methandrostenolone in osteoporosis, 1977 and 1981

Chesnut and colleagues (Metabolism, 1977) ran a 26-month double-blind study in 13 treated and 13 placebo postmenopausal women with osteoporosis, with total body calcium measured by neutron activation analysis as the main outcome.19 Sixteen completed the study (10 treated, 6 placebo); in those who dropped out, total body calcium changes through the time of dropout were similar to those in completers.19 Total body calcium increased 2% in the treated group and decreased 3% in the placebo group, and the authors wrote that "these data strongly suggest that long-term use of methandrostenolone in postmenopausal osteoporosis prevented bone loss; the possibility that it increased bone mass above initial values is less certain".19 Aloia and colleagues (Metabolism, 1981) ran a 24-month double-blind, randomized, parallel comparison with placebo and reported no significant changes in bone mass except a 6-month total body calcium difference of +11 g against -6 g (p = .05).20 They wrote that if methandrostenolone can produce an increment in bone mass in osteoporosis, "it was not readily observable with the sensitivity of the techniques employed in this study".20 Neither PubMed record states a sponsor or lists author affiliations, and neither gives a dose.19,20

Deeper analysis: Inkovaara and colleagues, 1983

Inkovaara and colleagues (Age and Ageing, 1983) gave 327 people over 65 (57 men, mean age 79.5) all possible combinations of calcium carbonate 3 g, vitamin D3 1000 iu, methandienone 2.5 mg and placebos daily for 9 months.17 The higher incidence of bone fractures in the placebo group was not significant, and, among the serum measures followed, the greatest changes occurred with methandienone, which the authors wrote "thus reduced osteoporotic activity and increased the muscular mass most effectively", while calcium carbonate "had the poorest effect".17 They described it as surprising that "coronary mortality was higher among those taking all three active substances".17 With two treatments the increase was not significant, but a pooled comparison showed a significant increase in coronary deaths, most significant (P less than 0.001) in those receiving vitamin D3 and methandienone.17 The PubMed record gives no sponsor, affiliations or stated limitations.17

5

Doses reported in studies and case reports

The doses below are those the sources report, and "not stated" means the PubMed record gives none; they are not recommendations.8,6

Table 5.1Doses reported in studies and case reports7 rows
SourceDoseFrequencyLength
Freed and colleagues, 1975810 or 25 mg/dayPer day; dosing times not statedNot stated
Hervey and colleagues, 19766100 mg/dayPer day; dosing times not stated6 weeks
Hervey and colleagues, 19817100 mg/dayPer day, alternating with placebo6 weeks per period, 6 weeks apart
Inkovaara and colleagues, 1983172.5 mgDaily9 months
Schänzer and colleagues, 19911640 mgNot statedExcretion followed after administration; length not stated
Schänzer and colleagues, 2006185 mgSingle doseMetabolite detected in urine up to 19 days after the dose
Habscheid and colleagues, 1999 (case report)1510 to 50 mg daily by mouth, with stanozolol 50 mg intramuscularly every other dayDaily80 days

In the 1975 trial of 13 weightlifters, three men withdrew because of side effects, systolic blood pressure rose significantly and body weights rose, which seemed to be associated with water retention.8 In the 1983 trial of people over 65, coronary mortality was higher among those taking all three active substances, including methandienone 2.5 mg daily.17 The IPCS monograph states that there is no serious risk from acute poisoning but that chronic use can cause harm.3 For orally active 17-alpha substituted anabolic steroids it states that they can cause abnormalities of hepatic function, shown as elevated hepatic enzyme activity in biochemical tests and sometimes as overt jaundice, and that peliosis hepatis has been associated with anabolic steroid use.3 For chronic use of the class it lists, among other effects, virilization in women, prostatic hypertrophy, impotence and azoospermia in men, acne, abnormal lipids, premature cardiovascular disease, abnormal glucose tolerance and psychiatric disturbances, and it notes reports of angiosarcoma and of a case of hepatocellular carcinoma in an anabolic steroid user.3

Case reports

Rosenfeld and colleagues (Journal of Medical Case Reports, 2011) described a 50-year-old man who presented with a six week history of abdominal pain, anorexia and weight loss after an eight week cycle of methandrostenolone use.10 Imaging was consistent with acute pancreatitis, a liver biopsy with intra-hepatic cholestasis and a kidney biopsy with acute tubular necrosis, and bilirubin was 922 μmol/L at presentation.10 Girgis and colleagues (Endocrine Practice, 2014) described a 35-year-old amateur body-builder who developed acute hepatitis with accompanying fever several weeks after starting high-dose methandrostenolone, taken with anti-estrogen drugs and diuretics.11 Habscheid and colleagues (Deutsche Medizinische Wochenschrift, 1999) described a 28-year-old body builder with jaundice after 80 days of metandienone and intramuscular stanozolol, whose serum bilirubin rose to a maximum of 77.9 mg/dl with renal failure (creatinine 4.2 mg/dl), and who improved as ursodeoxycholic acid was given.15 Poomthavorn and colleagues (2009) reported a 4-year-old boy and a 2-year-old girl given an off-label appetite stimulant syrup that contained cyproheptadine and methandienone.12 The authors wrote that methandienone undoubtedly caused precocious virilization in both children, that both cyproheptadine and methandienone were responsible for severe adrenal suppression in the boy, and that stopping the syrup led to partial regression of virilization in both and normalization of adrenal reserve function in the boy.12

Deaths with metandienone among several substances

Lehmann and colleagues (Forensic Science International, 2019) described a 34-year-old man who collapsed and died minutes after being found breathless; femoral blood held about 1 μg/L clenbuterol, about 56 μg/L stanozolol and about 8 μg/L metandienone, with trenbolone below the limit of quantification.21 Autopsy showed left ventricular hypertrophy and a right coronary artery with a small lumen, 3 mm in diameter; urine also tested positive for boldenone, clomiphene, drostanolone and trenbolone, with indications of testosterone or testosterone prohormones.21 The authors wrote that it can be assumed that the long-term consumption of anabolic androgen steroids caused apparently pathological changes of the heart, and that the combination of anatomical risk factors (small-lumen coronary artery, ventricular hypertrophy) and substance-induced risk factors led to the fatal cardiovascular failure.21 Darke and colleagues (Journal of Forensic Sciences, 2014) reviewed 24 anabolic-androgenic steroid positive cases at the New South Wales Department of Forensic Medicine, 1995 to 2012, and reported metabolites of methandienone in 20.8%; substances other than steroids were detected in 23 of the 24 cases.22

7

Bloodwork and markers

The app lists liver enzymes, lipids and hematocrit as markers to monitor for methandienone. The IPCS monograph lists a full blood count, electrolytes and renal function tests, hepatic function tests, testosterone, luteinizing hormone, prostate-related markers, blood glucose concentration and cholesterol concentration as tests relevant in the investigation of chronic anabolic steroid abuse.3 It states that anabolic androgens stimulate erythropoiesis, and that hypercholesterolaemia with a fall in high density lipoprotein cholesterol has been reported.3

The WADA 2026 Prohibited List, in effect from 1 January 2026, names metandienone under S1.1, anabolic androgenic steroids, when administered exogenously.1 Class S1 is prohibited at all times, in and out of competition, and all prohibited substances in the class are non-specified substances.1 In the US, 21 CFR 1308.13, the Drug Enforcement Administration's Schedule III list, includes methandienone (17α-methyl-17β-hydroxyandrost-1,4-dien-3-one) in its paragraph on anabolic steroids.2 In the UK, the Misuse of Drugs Act 1971 lists methandienone in Part III of Schedule 2, Class C drugs.5 The IPCS monograph, citing the ABPI Data Sheet Compendium (1993), states that the only legitimate therapeutic indications for anabolic steroids are replacement of male sex steroids in men who have androgen deficiency and certain rare forms of aplastic anaemia.3

The IPCS monograph prints no half-life, bioavailability or time-to-peak figure for methandienone, so the app's figures of ~4.5 hours, ~95% and ~1.5 hours have no matching figure in it.3 The monograph's statement that the elimination half-life from plasma is very short comes from its general section on anabolic steroids, in a passage whose next sentence concerns absorption from subcutaneous or intramuscular depots.3 The PubMed records of the trials give no sponsor statement and no author affiliations, the full papers were not read, and the osteoporosis trials and the 1986 glucose study give no dose.8,6,19,20,9 The trials with a stated number enrolled between 7 and 327 people, and the longest described here ran 26 months.7,17,19 No aromatization measurement for methandienone is reported in the studies summarised here, although the app lists aromatizes among its interaction flags for it.

What is Dianabol?

Dianabol is a brand name of methandienone, also written methandrostenolone and metandienone, an anabolic steroid with a 17-alpha methyl group.4,3

What is the half-life of Dianabol?

The app lists a half-life of ~4.5 hours for methandienone. In its general section on anabolic steroids, the IPCS monograph states that "the elimination half-life from plasma is very short" and prints no number.3 In a 1991 excretion study after oral administration, unconjugated metabolites reached maximum excretion rates between 4 and 12 h and conjugated metabolites III, IV and V between 12 and 34 h; these are urinary excretion timings, not a plasma half-life.16

Is Dianabol banned by WADA?

Yes: the WADA 2026 Prohibited List names metandienone, when administered exogenously, under S1.1, anabolic androgenic steroids, a class prohibited at all times, in and out of competition.1 All prohibited substances in the class are non-specified substances.1

Is Dianabol a controlled substance?

In the US, methandienone is listed among the anabolic steroids in Schedule III of the controlled substances regulations, 21 CFR 1308.13.2 In the UK, the Misuse of Drugs Act 1971 lists it in Part III of Schedule 2, Class C drugs.5

How long can methandienone be detected in urine?

Schänzer and colleagues reported a long-term metabolite in urine up to 19 days after a single 5 mg dose in 2006.18 A 2025 human administration study described further metabolites and called one a promising future candidate for a new long-term marker.23

Did Dianabol increase strength in trials?

Two double-blind crossover trials of 100 mg a day for 6 weeks gave different strength results.6,7 In 1976 strength and performance improved over each training period but not significantly differently on drug and placebo, and in 1981 leg performance and strength increased significantly on the drug but not during the placebo period.6,7 The 1981 authors wrote that "Although this action of methandienone might be described as anabolic, the weight gain produced is not normal muscle". In the 1975 trial of 13 weightlifters, improvements were significantly greater on methandienone than on placebo, and the PubMed record does not say what was measured.7

What side effects have been reported with Dianabol?

In a 13-person trial, systolic blood pressure rose significantly and three men withdrew because of side effects, which disappeared after the drug was stopped.8 Single case reports describe cholestatic jaundice with acute kidney injury and acute pancreatitis, acute hepatitis with fever (also on anti-estrogens and diuretics), and, in two children given a syrup that also contained cyproheptadine, virilization, with adrenal suppression in the boy.10,11,12 In a 1983 trial of people over 65, coronary mortality was higher among those taking all three active substances, including methandienone 2.5 mg daily.17

Does methandienone bind the androgen receptor?

In rat and rabbit skeletal muscle and rat prostate preparations, binding of methanedienone to the androgen receptor was weak, with relative binding affinity values less than 0.05.13

What has methandienone been studied for in clinical trials?

Studies from 1975 to 1986 covered methandienone or methandrostenolone in athletic men, in people over 65, in postmenopausal women with osteoporosis, and in patients given glucose tolerance tests.8,19,17,9

12

References

  1. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026, in effect 1 January 2026. WADA Prohibited List 2026
  2. US Drug Enforcement Administration. 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations. eCFR 21 CFR 1308.13
  3. International Programme on Chemical Safety. Methandienone. Poisons Information Monograph 905. Author: Ferner RE, 1994; editor Ruse M, 1998. IPCS monograph PIM 905
  4. Freed DL, Banks AJ. A double-blind crossover trial of methandienone (Dianabol, CIBA) in moderate dosage on highly trained experienced athletes. Br J Sports Med 1975. PMID 1102048
  5. Misuse of Drugs Act 1971, Schedule 2, Part III (Class C drugs). legislation.gov.uk. UK Misuse of Drugs Act 1971, Schedule 2
  6. Hervey GR, Hutchinson I, Knibbs AV, et al. "Anabolic" effects of methandienone in men undergoing athletic training. Lancet 1976. PMID 61389
  7. Hervey GR, Knibbs AV, Burkinshaw L, et al. Effects of methandienone on the performance and body composition of men undergoing athletic training. Clin Sci (Lond) 1981. PMID 7018798
  8. Freed DL, Banks AJ, Longson D, et al. Anabolic steroids in athelics: crossover double-blind trial on weightlifters. Br Med J 1975. PMID 125133
  9. Godsland IF, Shennan NM, Wynn V. Insulin action and dynamics modelled in patients taking the anabolic steroid methandienone (Dianabol). Clin Sci (Lond) 1986. PMID 3539458
  10. Rosenfeld GA, Chang A, Poulin M, et al. Cholestatic jaundice, acute kidney injury and acute pancreatitis secondary to the recreational use of methandrostenolone: a case report. J Med Case Rep 2011. PMID 21470406
  11. Girgis CM, Kuo I, Handelsman DJ. Acute hepatitis and fevers in an amateur body-builder: a new complication of synthetic androgen abuse? Endocr Pract 2014. PMID 24641932
  12. Poomthavorn P, Mahachoklertwattana P, Khlairit P. Childhood virilization and adrenal suppression after ingestion of methandienone and cyproheptadine. J Pediatr Endocrinol Metab 2009. PMID 19618666
  13. Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology 1984. PMID 6539197
  14. Parr MK, Zöllner A, Fusshöller G, et al. Unexpected contribution of cytochrome P450 enzymes CYP11B2 and CYP21, as well as CYP3A4 in xenobiotic androgen elimination - insights from metandienone metabolism. Toxicol Lett 2012. PMID 22885098
  15. Habscheid W, Abele U, Dahm HH. Severe cholestasis with kidney failure from anabolic steroids in a body builder. Dtsch Med Wochenschr 1999. PMID 10506840
  16. Schänzer W, Geyer H, Donike M. Metabolism of metandienone in man: identification and synthesis of conjugated excreted urinary metabolites, determination of excretion rates and gas chromatographic-mass spectrometric identification of bis-hydroxylated metabolites. J Steroid Biochem Mol Biol 1991. PMID 2031859
  17. Inkovaara J, Gothoni G, Halttula R, et al. Calcium, vitamin D and anabolic steroid in treatment of aged bones: double-blind placebo-controlled long-term clinical trial. Age Ageing 1983. PMID 6346829
  18. Schänzer W, Geyer H, Fusshöller G, et al. Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. Rapid Commun Mass Spectrom 2006. PMID 16804957
  19. Chesnut CH 3rd, Nelp WB, Baylink DJ, et al. Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass. Metabolism 1977. PMID 319322
  20. Aloia JF, Kapoor A, Vaswani A, et al. Changes in body composition following therapy of osteoporosis with methandrostenolone. Metabolism 1981. PMID 7026971
  21. Lehmann S, Thomas A, Schiwy-Bochat KH, et al. Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone). Forensic Sci Int 2019. PMID 31499423
  22. Darke S, Torok M, Duflou J. Sudden or unnatural deaths involving anabolic-androgenic steroids. J Forensic Sci 2014. PMID 24611438
  23. Steff J, Molaioni F, Schlörer N, et al. Reduced and rearranged metabolite structures after metandienone administration: New promising metabolites for potential long-term detection. J Steroid Biochem Mol Biol 2025. PMID 40473058